Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Please pay particular attention to jane and cdel. Both are "true" market makers, aka market manipulators in recent month.
It seems both were forced to reverse course, and need to load up. But they could also pounce back anytime.
Anything below $2 is a steal! We ought to bury these shits forever.
Only way to win for big boys is to steal, until we are united...
My takeaway of changing auditor from Marcum to Cherry Bekaert LLP is hugely positive. My speculation is that
1) The company's repeatedly delays of financial filing have had something to do with Marcum which might be deliberate in the most recent filing delay, and Linda finally got fired of and decided to move on with other firm. It seemed the change was intentionally driven by Marcum making Linda to say enough... and
2) Now Marcum is free of taking a position buying NWBO.
Shorts are bleeding everywhere noways. NWBO's shorts have taken notice. With average IQ, the wolfpack naked short knows what they have to do.
TLD or data release in whatever form will be announced no matter what, and each passing day is a day close to the revelation.
There are too many positive fronts ongoing, and please hold your shares or even add more if you can
Any price below $2 is a steal!
Shorts have been losing in the past year, and is losing big betting Biden administration will tighten, interest will increase...
Nowadays, there is no difference between Dem and Republic governments. Both cater to the instant demand of the current generations, ignoring the future generation, creating all kinds of bubbles.
Don't care about the future has become the trend principle of the free world.
Anyhow, shorts are domed to lose big holding shorted NWBO shares, it's just the time, and they will lose bigger under Biden's first year, a year to appease to the popular demand of the people, a year of printing even more money than Donald ever had
Somebody thinks naked short wolfpack has to follow the laws and regulations simply because all trading is now digitized.
Never heard or unable to understand the dark pool of underground world, and yes all transactions are recorded digitally?
Never heard or unable to understand market makers can legally carry balance each and every reporting period, and the balance is a mix bag of numerous different stocks, derivatives, etc.,[it's allowed by the law to "create shares" to provide liquidity, but the law can be readily taken advantage of by its own setting] for which SEC little heads will find either too complex to understand or too huge a burden to verify, or at least watch some porn will be easier to kill time.
That legal carried balances change with time in terms of stocks and derivatives of their carrying dynamically.
At the choosing of MMs or their clients driven by greediness and savvy or dumb decision, buried in the darkpool/legally carried balance week after week, quarter after quarter, and year after year are stocks naked shorted
For some stocks trading in OTC particularly, and stocks of small developing stage biotechs, the odds are high that the stocks will disappear, and the name of the stocks would disappear from the darkpool/carried balance, and new stock names would be added in the never verified, ever-changing, mixed-bag dynamic flowing balances. And in case SEC staff tired of watching porn and decided to get to the bottom of one MM's illegal practice, before SEC can sniff around, the balance swapped with the balance of other MM, in part or completely, though never heard SEC has ever gone that deep.
It's an illegal but profitable practice "sanctioned by SEC" and it will never change.
The perpetrators are laughing to the bank pissing SEC and vast numbers of investors in most cases, that makes it never-get-punished, SEC-sanctioned, profitable practice....
But this is what I know they may laugh to the banks for other stocks, they will pay the price for naked shorting NWBO.
But number two, I do think the naked short wolfpack by now must understand their decision was wrong, and they are trying to find the right time to clear those naked short shares, which we will see when that is going to happen. If they are smart enough, better before TLD or the announcement re trial data in whatever form.
[my personal guess is that the naked short wolfpack has unloaded some naked short shares already, it may not be of a significant number. And I do believe the pack understands it has to unload all their positions because even them understand DCVax-L trial will be a success, maybe they are waiting to see as we long do how successful the trial will be.]
I realized it's hypothetical, but defending the company in this way, despite hypothetical, is absurd.
Don't think Linda is anyone close to a crook. As a matter of fact, my investment decision, unlike many others who dislike the fact that NWBIO has been run by two successful high-profile former lawyers, was initially made exactly because of that very fact, which suggested to me NWBIO might be run in a way of constant walking on the borderlines [timeline delayed, delayed, and delayed, kicking the can, carrot dangling, and you named it, which are all part of my understanding], but the outcome pursued thereafter would not be anything close to an instant rich/results for they are already rich, because the outcome has to be legendary if science is solid and continued to be proven solid.
Remember go big or go home! Only very successful persons like Linda and Les have such luxury to run a company "like playing a toy," not for instant results, not succumb to any unnecessary unwanted external pressure.
Only thing I have ever complained is Linda's greediness of awarding herself too many options/warrants at too low target prices. Even today, I still don't think Linda had no ways to cause a much higher historic lowest price, partly because she could make all up by rewarding herself more options/warrants at lower price, but for us retail investors we have had to put much much more hard-earned money to average down to make up, which is suck to say the least, although it's a trajectory I determined to follow.
After both UK and Germany were somewhat onboard which further validated the science, I finally decided to go big on my NWBO investment. Occasionally selling some, but always bought back and more. Now I (my family fund) is too deep in NWBO which has become my largest single stock holding ever, along with just a few other stocks in much much less significance.
IMHO, I have the trust that Linda would have let the public know if the trial's primary endpoint were a miss. For me that's the very basic of my belief; defending the company for whatever reason if the trial were a miss in the primary endpoint without a public announcement shows lack of trust in the company and absurd blindness.
Of course as I said repeatedly, it is a moot point to further discuss this hypothetical situation, because it's highly probably the trial is significant in meeting its primary endpoint.
Good luck to you!
welcome onboard again my friend, agree on all you said except that I do think investors can have a sigh of relief we have not had negative news yet wrt the trial since data was locked on 5 Otc.
All the best and good luck!
Some things come to my mind in this minute: [this post is not intended to reply to fox, sorry]
nwbo trial registry has not been updated since Oct 2016, even after the partial halt for new patient screen was lifted by FDA in early 2017
if lifting of a halt has been ignored why this revised endpoints?
Personally I don't want to have anything be documented and later find it may hinder flexibility in dealing with FDA as FDA is such a rigid beast
All signs points to positive outcome of the trial, hereby the company, its investors, and most importantly for GBM patients -- no distraction from the company to launch new trials, or buying a tiny biotech to expand pipelines,
No major shareholders and insiders have cashed in, leaving huge mountain high, ocean deep derivatives and shares intact....
All in all not much of a fanfare for anything [expanding patents, manufacturing progress,...], but deafening quietness!
utter nonsense.
First most investors don't think there is a tiny chance of trial failure in primary endpoint
Second if it were a failure measured by primary endpoint, the trial failed by its own definition according to its own SAP. It failed PERIOD
No excuse to withhold the data to the public because of further analyses, or confirmation analyses, or data mining to find other silver lining
Even afterwards the fate of the trial now deemed failure may reverse course (yes there is chance there), it doesn't change the trial failed initially according to its SAP
Thus the company must release the news to the general public even if ultimately the trial would be saved and regained chance of approval.
It's two different things. First you must disclose trial failed in terms of its primary endpoint not meeting predefined metric, and later you also must disclose the trial still has chance of showing both safety and efficacy derived not from its primary endpoint meeting its predefined goal, but from other supporting and persuasive data.
There will be no leeway; otherwise it will become the Old West.
Bottomline: this is a moot point, because the trial is highly likely to meet its primary endpoint in a statistically significant way, hereby the trial will be a success!
will be approved in UK first within a foreseeable future, followed by EU and the US.
Linda has been focused on the ultimate commercial success of DCVax platform, not everyday's price ups and downs and some retail investors' mood swinging. By doing so she can avoid trivial and potential disruption such as threats of potential lawsuits (in American you can suit anybody with anything with any negative clue real or not real!) Yes she has the fiduciary duty for her shareholders, but not for day to day share price swing!
She wants to give true shareholders a price of, for example $5 as starter when a major news is released and save the long the struggles to consider selling some of their shares when the price experiences ups and downs, for example in the range of $1 to $3.
Not necessary exactly would happen like the above, but I do like the scenario, and I hope it goes exactly that way.
It's a steal to have a share price below $2 now.
It's my last post for today. GL.
That's golden sukus. I have no doubt about it
No. The company is obligated to go public if its trial fails PERIOD.
For example, if the trial's primary endpoint is not met, there will be no doubt to anyone, FDA, or any average investor or to any person with common sense, that the trial fails. As a result the company must/should notify all shareholders in a news release.
Of course, failing in the primary endpoint doesn't mean there is no chance for the agent/treatment of the trial to be ultimately approved by FDA, and the trial may later actually be approved to be successful with persuasive results of efficacy and safety derived from its meeting some secondary endpoints and peripheral testing results such as immunodeficiency of patients, etc, after painstaking efforts and further more detailed analyses and regulatory negotiation, etc.
The above two doesn't contradict one another. Yes the company has the obligation to disclose if its trial fails in terms of the trial's primary endpoint (if that is not defined as failure, then no clearer definition of trial failure ever exists; don't tell me only if the trial fails in both its primary and secondary endpoints can it be defined as failure). And yes, the status of the trial can in the end reverse course and be defined as a success after painstaking efforts and persuasive data analysis support, which can only come in much later time.
Specifically in the case of nwbo, it is more than likely the trial has met its primary endpoint in a statistically significant way, thereby DI's comments to several callers that the company would have notified shareholders if the trial had failed. It in itself doesn't mean DI has been unblinded. However, if he has not, if the trial's primary endpoint is a miss, statisticians must notify the company!
Now, with what we have known (the blinded blended trial results and the subsequent data update) the trial will definitely meet its primary endpoint, not because the standard of the trial is lowered but the fact all other trials, including the FDA approved Novocure device has not yielded better results than DCVax-L trial in terms of safety and efficacy, if the unblinded data is at least as good as the blinded blended data we have known.
IMO from now on, nobody should talk about whether this trial is a failure or not, instead they should talk about how successful this trial will be! Let me repeat what I has said for a month or so:
A price below $2 is a steal!
sukus, same here -- I meant I have cut my food consumption and done more exercise, not because of the up and down of nwbo share price, but in general my age and desire for a quality of life as long as it can give me.
Not worry about nwbo's eventuality of regulatory approvals and blockbuster commercial status. I have slept well nowadays, but it really was some tough time when the stock price was trading in teens, despite blessed of buying at that time.
I think the SEC would not agree with Linda for a 60-days of delay, if not for other issues which are not revealed in the now filed Q [I think the company was initially intended to hold as long as it took but the outcry of retail investors changed their mind, left out some concrete news bits].
Linda has to file today maybe because it's still premature to reveal what were really holding them off in the first place.
The filing today itself and the content of it has removed a nagging issue which is they are not sitting on some material negative stuff, so the opposite must be true, and I believe it.
Good luck [this is my last post for today]
Good for you sukus. I guess today's price could be the floor after 10Q is released, and the company seems to have enough to reach announcements of TLD and/or publication, if not earlier with some other positive news.
The highest price I paid in my average up process is around $1.88, and the lowest from $0.35 all the way up...
Best
To be fair Jerry at the time you permbears were claiming the company would soon go under and no serious person(s) would throw a penny to a soon bankrupted company.
So definitely according to you at the time nobody would give a loan and it seemed Linda was a brave lady to throw some serious money to keep the company alive.
We are now up a whopping 800% in share price. Do you think she deserves it?
Come on Jerry at least admit your misjudgement and move on.
Another 800% rock up is in the making. If money doesn't bite Jerry, you can make some serous money too, which I don't think is against your obligation, outside of your work to be exact.
The five fk long years long-term data is there which is unprecedented, exclusive, all the prior trial data is there including now hugely successful everybody-doubt-it Novocure, the statistics of standard of care data is there...
Anything below $2 is a steal. No more time to waste typing Jerry.
Short MMs JANE & CDEL seem for the first time in a while to just reverse course, now seem to be buying
Close around $1.5 today
we are at 1.2 million more shares traded above 10-day average volume now
Close at $1.5 will be a good lesson for a lot of penny flippers
You will be paid off handsomely. I have been holding enough for retirement several times if what I foresee comes true. Despite that, still have dry powder ready for disposal
The primary endpoint is met ss, at least some secondary endpoints are met ss pending announcement predicted based on what we have known on both DCVax-L trial and all other failed GBM trials so far...
Linda is sitting on something good and planning her next moves
For that I am waiting patiently as well or as long as it will/should take
[this is my last post so yes tryn2 I believe what you said is true. GL]
Thank you and good luck to your other endeavors on behalf of MMs jane and cdel, who are having one more field day today, yesterday being somebody's divorce ...
Today being yours departure [assuming you really had something to sell] and apwriter's as well, and of course some others'
All having an electronic trace
we will miss you all on our way to a $5 opening boom 'cause Linda refuses to have a smooth ride: $1.4, $1.6, $1.8...$2...$3...
It's a natural process to remove weeds in the garden of stock market, and it will be particularly true for NWBO for all its abnormalities known to all
Take a look at this pre-pumper turned 180° today just after a short tenure as an investor: [there are plenty in real life, because it's called real life]
https://twitter.com/apwriter
As sad as it seems to be, it is actually a buying sign for obvious reason
I have put ignore of too many in this board, and reading only a few. Even that, it seems it is still a waste of time
This process is ongoing as Linda works her ass off to maximize her interests and coincidentally ours as well.
In this sense I understand you. But unconsciously lots of investors are just doing the same and you can include 99% of the total negative comments in this category, leaving that 1% from the naked short wolfpack, or those paid to post, or those claim to have no shares, long or short, but post 24/7 for years.
None of these matter in the end. In the grand thing of matter, DCVax-L will be approved as a treatment for ndGMB patient, and perhaps for rGBM patients as well, suggested by the first secondary endpoint, of course if data shows strong evidence it helps rGBM patients as well.
because we know the primary endpoint will be readily met ss, and it's most likely some of the secondary endpoints will also be met ss.
For a treatment, which is easy to administerd, almost no side effects, a so so treatment effect will easily warrant an approval, let alone its effects being better than anything on the market, based on the blinded blended data we all have known.
I am not sarcastic or something negative about your action but rational.
For a total of $9k worthy of shares you claimed you owned (about 5k shares at about $1.8 per share you revealed a couple of days ago), really you were taking the nuisance to reveal you have sold 2/3, ie, a whopping 3,333 shares, and keep the rest whopping 1,666 to let it run, FULL PROFESSOR.
What a life! You think you can contribute to a few pennies of price drop? Even so,
Again what a life for a Full Professor.
There are other branches of flowing processes going in parallel as well. Just give a rough incomplete picture:
Buyout or partnership negotiation...
Preparation for public release of TLD and publication of trial data, intended to release within a short period apart or simultaneously...
Regulatory negotiations with RAs, particularly FDA for various possibilities discussed before, including using the data available from the current DCVax-L trial for nGBM for the approval of rGBM as well...
Uplisting to Nasdaq or NSE....
Squabbling with SEC for some ongoing and newly found trivial...
Rewarded or about to reward themselves with options in a more than generous way as Linda has demonstrated over the years ...
Bound by the law, and Linda's personal intention together, she may want to wait for the right time to release the above, either piece by piece, or in combination of some, or ...
With overwhelming good news to dilute some negative parcels of news such as rewarding themselves with overly too damned good options...
At this point only thing that makes sense that can explain the current situation of the delayed-than-usual Q3 and TLD, and as well as no significant (or almost none) warrant exercising, or even no talks about warrant further extension or much needed financing ...
is either an outright buyout negotiation or a major partnership discussion, hence the company is in a quiet period.
All other speculation just cannot explain, including my previous speculation of regulatory negotiation.
If a buyout or partnership speculation is true, then the company definitely cannot release Q3 and may not be in a position to release TLD bound by pre-arrangement of first negotiation right.
Of course if the first negotiation such as with Merck falls apart, then the bound would be relieved.
And if the above speculation is true, as I said before then the price will substantially appreciate as a harbinger of a closed or close to closed deal is made.
Linda should serve as next director of CIA for nobody in the US can keep a secret the way it should like her!
Most likely regulatory related. Needing that confirmation for a pair of lucky breaks, plus usual Linda Powers greediness in terms of option rewards upon reaching a couple of milestones
I do think this time her greediness is aligned with our final payout as retail investors, ie. I don't care she will be a billionaire or multi-billionaire as long as there will also be a thousand if not a ten of thousand new millionaires.
Above all, there will be an effective and safe treatment for GBM patients, and a potentially cancer curing vaccine platform either alone or in combination with other therapies.
We all should be happy. I can bear the wait.
The narrative may be like this:
The company submitted only one and same SAP to four RAs. As we have already known by now both UK and Germany have accepted the revised, reordered endpoints while the company might be still waiting for FDA's "buyin" of the revised endpoints and/or the approvals of rGBM in addition to the initial ndGBM based on the same current trial data before datalock. FDA might have been quiet on the revised, reordered endpoints, and the company may want a definite nod from FDA, ie. the buyin.
On 5 October, the company announced datalock which intentionally omitted a specific timeline for TLD, partly because FDA might have said to the company, "well, for all the requests of yours, let's first see the goods (the unblinded data)." These requests, besides the "buyin" of the revised, reordered endpoints could also include other requests such as fast track designation, accelerated approval, priority review designation, the approvals for rGBM in addition to the initial ndGBM (it may not be exact and specific as the above, just saying there may have been other requests besides the "buyin" of the revised SAP and/or the approval of rGBM).
Hence, there is no specific timeline in 5 October news release since the ball would have been first landed in FDA's court, and hence DI's comment, "we have been unable to ask CRO, the statisticians," because for quite some time after datalock, the company had still been blinded according to the agreement with FDA, while FDA and/or maybe the Steering Committee (SC on behalf of the company) have been first unblinded. And there have been Q&A going on between FDA and SC (on behalf of the company) and the statisticians.
FDA, bound by Covid-19 related issue has moved not as fast as we would expect, and its answers to the various requests from the company could only be forthcoming when it takes its time in today's Covid-19 environment.
But, I believe at this time, FDA has provided its initial comments to the company, the company has been since unblinded, and both the company and FDA have been trying to reach a consensus.
Until such a consensus is reached we may have to wait a bit longer. But when the time comes we may be pleasantly surprised with the results which, in addition to the long waited TLD, may also include an agreement for the company to submit BLAs for both ndGBM and rGBM based on the same trial data, let alone the acceptance of publication of the trial data in a first tier journal, etc.
The above may have been ongoing in parallel with company's preparations for TLD release and publication of the trial data. And I believe the delay of the 3rd quarterly report has also more or less something to do with the above conditions.
Although it can be any day now, in a sense I personally feel the longer the wait, the better the outcomes.
The bottom line is that with stellar data, whether the company has had FDA's "buyin" now or not really doesn't matter, despite potential delays or bumps on the road of approval, FDA will have to ultimately approve DCVax-L for GMB, because I cannot see any negative recommendations that could come out from any ADCOM called upon by FDA.
You said, " I do not think that is the situation in this case, for a multiplicity of reasons"
I don't think that is the case either, hence why taking the gigantic effort to beat the dead horse for a moot point?
Happy New Year!
Maybe you can answer the following specific question with yes or no ONLY, which I initially posted for Bio (as you can imagine he ignored the yes or no answer asked, and instead wrote a lengthy nonsense in response to get around it as usual):
The question I posted is
"Assuming the company knew its DCVax-L trial failed in terms of its primary endpoint in Nov, would the public have been notified by now more than a month after the company knew its trial failed in its primary endpoint? "
What's your answer Doc?
You should understand nobody relies his/her investment on that so-called "4-day rule," and whether it's applicable here or not is not the issue, but no one should deny it's a one more layer of insurance besides the rock-solid science and the blinded data we have known for the trial (if your answer is yes to the question above of course).
You know the company announced data lock around 5 October, today is 31 December. Any reasonable person would assume the company (at least Linda) has been unblinded for a quite while, probably at least more than a month.
Now back to the question, if the trial failed in terms of its primary endpoint according to the revised SAP, do you think the company would keep it from the public for more than a month, or two weeks, or two months, or a week?
Because we know the foundation of the science behind the trial and the blinded data, we pretty much are assure that the primary endpoint would be readily met in a statistically significant way, hence a reasonable person with the above knowledge would not think the trial would fail in terms of its primary endpoint, and hence no news is good news as of today, and hence we have one more layer of insurance in our investment, unless you think Linda and/or Les are crooks.
Now somebody seemingly for purely argument purpose has persistently "denied" the very high probability that the trial is at least a success in terms of meeting its primary endpoint, by "arguing endlessly at any chance on whether there is a 4-day rule or whether such a rule is appropriate for TLD release. In doing so, he/she gives an impression for newbies that the trail is still very likely a failure in terms of not meeting its primary endpoint according to the revised SAP.
That's the problem Doc. You may have been used to the very busy ER working environment, and it's hard for you to sink in. That's okay. We all have problem understanding things correctly sometimes.
On the other hand, you should also realize you are in no position to judge as you seems to be a person who is easy to be carried away by something superficial. Seemingly eloquent talking with false/misleading information is nothing more than a nice clothing doc.
Happy New Year!
Thanks Doc logic for your comments, and the constant reminding us of those 17 missing SOC/placebo patients.
My opinion is we are de-risked by the newly and reordered endpoints, and the obviousness that the primary endpoint should be readily met ss; otherwise we should have been notified by the company.
My guess why we have not seen the quarterly and/or TLD is that the company is either in regulatory negotiation for potential approval of rGBM besides ndGBM or a potential buyout/partnership deal with BP.
If the later is true we should see significant price hikes soon if the deal is made or close to be made, simply because the potential acquirer should take a share as big as possible via open market buying.
Thing could change very drastically starting after New Year Day.
I am also weighing on buying more shares before end of today's trading. The only hurdle for that is I already have had too many shares.
Typical biosectinvestor, done discussion with you! GL
You have had too much nonsense recently. What's the matter with you?
Please answer the following specific question with yes or no ONLY:
Assuming the company knew its DCVax-L trial failed in terms of its primary endpoint in Nov, would the public have been notified by now more than a month after it knew its trial failed in its primary endpoint?
your answer:
OTCQB Certification
Well if NWBO has been in regulatory negotiations which prevent it from releasing quarterly as part of activities after the end of the quarter, we can only see the quarterly after the negotiations bear fruits.
Anyhow picked up 30k more shares averaging up this morning around $1.38.
[Noticed absence of some MMs in this morning's dump, who showed up as price started come back!. One of these MMs is Jane]
Nonsense
Fox and AVII and you are incorrect to say that the DCVax-L trial results are not the results of a randomized placebo controlled trial.
The trial results are obtained from a randomized placebo controlled trial, which will compare OS and PFS of treatment arm with the placebo arm within the trial as secondary endpoints.
The fact that its primary OS endpoint results are compared with those of comparable trail placebo arms of other similar trials doesn't change the fact the DCVax-L trial is a randomized placebo controlled trial.
As the publication of DCVax-L trial in either NEJM or Lancet, you are even far off. The merit of publication in high profile journals is always focused on POTENTIAL IMPACT, and quality of the data.
No results of any trials in the realm of GMB treatment will have more positive impacts than those of DCVax-L trial to be revealed if the results repeats or better than what we have known from the blinded blended publication and its subsequent update.
Open your mind a better open, and don't miss the opportunity!
Need to run with friends for some fun this afternoon. To many soft FUDs recently from amateurs, "Full Professors." Must have been not enough of cheap shares. I bet we will see a publication of DCVax-L trial results in either NEJM or Lancet soon. Do you want to bet?
They are not angry they are mad
why wonder IkeEsq. In effect 99% of information from the media let alone message board is just that, speculation, I assume, I think, etc.
As a result, I rarely participate, let alone response to any known Fudsters.
The status of investing in nwbo at this point is just waiting for the next news, probably TLD, and the market has actually spoken in favor of DCVax-L's approval by 4 RAs (at this stage before TLD, the market has given NWBO a firm above $1 billion mc saying it is confident...)
Very pathetic of that guy. he always gave a rare example, ran long and seemingly useful introductory, and always came up with a negative conclusion at the end against nwbo.
any average Joe on the street can google and come up with ten times more of the cases with completely different outcome versus the rare case he cited.
the fact is that FDA will follow its ADCOM recommendation 95% of the times, and yet he cited one case where FDA went against it, to combat NWBO. LOL
how about you should have listened to him around early this year when the price hovered around $0.14-$0.19 and sold all?
because according to him, this company would have long gone out of business.
Exactly
Doubt it flipper since Linda has not issued 10Q yet and she must have known the unblinded results which prohibits her from making a financing deal without proper disclosure.
[Also Linda has had enough cash to last for six months. Only warrant exercising based on OS share count changes in the last month or so has put approximately ten-twenty million into the coffer of nwbo]
According to AVII himself/herself, he/she admitted he/she is an amateur having no proper professional credentials whatever in doing any credible biomed analyses.
As far as I know, he/she has gone astray since his/her investing in a Canadian biotech company called Biomira which later moved to the US and changed its name as Oncothyreon (ONTY) with heavy losses more than 15 years ago.
He/she has also said in the past his/her daughter might have suffered some kind of medical malpractice that had driven him/her in the studies and research of some biomed issues of his/her interests, including FDA related practice, etc., which is the only thing he/she has my respect in general.
But anyone can see from checking his/her posting history on NWBO, he/she has always magnified negative issues, real or imagined, while ignoring, downplaying any positive effects. According to him/her and the other usual few bears in this board, NWBO should have long gone out of business with a failed trial and no further financial lifeline.
His/her appearance has always been a sign of desperation of those who hate NWBO!
Yes, I have since put him/her in ignore.